Hospital Medicine Alert – January 1, 2016
January 1, 2016
View Archives Issues
-
Can We Safely Discharge Patients on the Weekend?
ABSTRACT & COMMENTARY: The link between weekend discharge and 30- and 90-day readmission rates.
-
Optimal Beta-blocker Dose Post-MI
Beta-blocker therapy after acute myocardial infarction was retired as a hospital performance measure because its almost universal acceptance removed its discriminating value. However, it is well known that clinically used doses are significantly lower than those achieved in the randomized trials, establishing their mortality-reducing benefits.
-
Idarucizumab Injection (Praxbind)
The FDA has approved the first reversal agent for a direct oral anticoagulant. Idarucizumab is a humanized monoclonal antibody fragment derived from an IgG1 isotype molecule. -
Ceftazidime-avibactam — Formulary Considerations
Ceftazidime-avibactam is a new beta-lactam/beta-lactamase inhibitor combination approved for the treatment of complicated intra-abdominal infections in combination with metronidazole, and complicated urinary tract infections, including pyelonephritis in patients with limited alternative treatment options.